The impact of the Th17:Treg axis on the IgA-Biome across the glycemic spectrum

Heather T. Essigmann¹, Kristi L. Hoffman², Joseph F. Petrosino², Goo Jun³, David Aguilar³, Craig L. Hanis³, Herbert L. DuPont¹,4, Eric L. Brown¹*¹

¹ Center for Infectious Disease, Division of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas Health Science Center, Houston, TX, United States of America, ² Alkek Center for Metagenomics and Microbiome Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, United States of America, ³ Human Genetics Center, Division of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas Health Science Center at Houston, Houston, TX, United States of America, ⁴ Kelsey Research Foundation, Houston, TX, United States of America

* eric.l.brown@uth.tmc.edu

Abstract

Secretory IgA (SIgA) is released into mucosal surfaces where its function extends beyond that of host defense to include the shaping of resident microbial communities by mediating exclusion/inclusion of respective microbes and regulating bacterial gene expression. In this capacity, SIgA acts as the fulcrum on which host immunity and the health of the microbiota are balanced. We recently completed an analysis of the gut and salivary IgA-Biomes (16S rDNA sequencing of SIgA-coated/uncoated bacteria) in Mexican-American adults that identified IgA-Biome differences across the glycemic spectrum. As Th17:Treg ratio imbalances are associated with gut microbiome dysbiosis and chronic inflammatory conditions such as type 2 diabetes, the present study extends our prior work by examining the impact of Th17:Treg ratios (determined by epigenetic qPCR lymphocyte subset quantification) on the IgA-Biome across diabetes phenotypes identified a proportional relationship between Th17:Treg ratios and alpha diversity in the stool IgA-Biome of those with dysglycemia, significant changes in community composition of the stool and salivary microbiomes across glycemic profiles, and genera preferentially abundant by T-cell inflammatory phenotype. This is the first study to associate epigenetically quantified Th17:Treg ratios with both the larger and SIgA-fractionated microbiome, assess these associations in the context of a chronic inflammatory disease, and offers a novel frame through which to evaluate mucosal microbiomes in the context of host responses and inflammation.

Introduction

Secretory immunoglobulin A (SIgA), the most abundant immunoglobulin subtype produced by humans, maintains intestinal homeostasis by actively selecting the residents of the gut
microbiota [1–3] and providing protection against pathogenic microorganisms and toxins [4, 5]. Additionally, SlgA regulates bacterial gene expression and motility, thereby impacting host metabolism, innate immune responses, and the integrity of the gut epithelium [6–11].

The fitness of the mucosal associated lymphatic tissue (MALT) (e.g., the gut, bronchus, conjunctiva, lacrimal ducts, salivary ducts, nasopharynx) can be measured by the diversity of the SlgA repertoire [11, 12]. The primary purpose of the MALT is to generate and transport SlgA to these host/microbiota interfaces where they target select taxa, thereby generating distinct SlgA coated (SlgA⁺) or SlgA uncoated (SlgA⁻) microbial communities, i.e.: the IgA-Biome [12–14]. Because the quality of the SlgA response can be affected by T-cell phenotypes and mucosally-imprinted/activated plasma cells circulate across the MALT (including in the oral cavity lymphatics and Peyer’s patches and lymphoid follicles of the small and large intestines) [11], we examined the impact of Th17:T-regulatory (Treg) T-cell ratios on both the salivary and gut IgA-Biomes (i.e., the SlgA-coated and SlgA-uncoated microbes) in the context of diabetes phenotypes because: i) the oral cavity is the point of entry where microbes first encounter SlgA and some SlgA-coated taxa are present both in the oral cavity and the gut e.g., Lactobacillus, Haemophilus, and Prevotella [15–17], and ii) the impact of the Th17:Treg ratios in the context of the IgA-Biome and dysglycemia has not yet been explored and will better define the impact of the Th17:Treg/SlgA axis across mucosal microbiomes (Fig 1).

Production of SlgA of high affinity and specificity is T-cell-dependent [18–22], and the nature of the T-cells populating the lamina propria and the lymphatic tissues of the gut and other mucosal sites can significantly impact the SlgA repertoire [23–26]. Without T-cells, high affinity, antigen-specific antibody responses are virtually nonexistent [27, 28], and poly-specific, cross-reactive SlgAs of low affinity and specificity dominate [19, 20, 22, 29–33]. The importance of a highly diversified (specific) SlgA repertoire in the maintenance of a complex gut microbiome is exemplified in mice with a specific mutation in activation induced cytidine deaminase (AID) that allows for antibody class switching in the absence of affinity maturation resulting in the production of normal amounts of low-affinity SlgA [34, 35]. The absence of high-affinity SlgA in such AID mutants skews the composition of the gut microbiome [36].

Immune dysregulation plays a key role in the pathogenesis and progression of type 2 diabetes [37]. Type 2 diabetes presents with impaired natural killer cell and B-cell function, abnormal proliferation of macrophages, and imbalances in the Th17:Treg T-cell axis [37–39]. Despite developing from a common precursor, Th17 and Treg T-cells have opposing inflammatory roles evident in autoimmune disease, infection, diabetes, and gut microbiome health [23, 24, 26, 40]. Tregs maintain homeostasis in part by regulating SlgA abundance and specificity, while SlgA reciprocally controls T-cell responses in the gut [41]. Skewed Th17:Treg profiles, observed in a number of chronic inflammatory conditions [40, 42], are due to both an increase in Th17 cells [23, 43–46] and a reduction in Tregs—the latter of which are vital in reversing the insulin resistance that typifies diabetes progression [46–49]. IgA production is also altered in those with hyperglycemia [21, 50, 51], with elevated serum IgA correlated with diabetes sequelae, including nephropathy, neuropathy, and vascular complications [3, 37, 50–57].

We recently conducted a preliminary study of the IgA-Biome, 16Sv4 rDNA profiling of the microbiota based on their SlgA coating, by diabetes status in a group of Mexican American adults [13]. We observed relative shifts in the SlgA⁺ and SlgA⁻ bacterial communities distinct from that of the overall microbiome [13], highlighting the unique perspective of IgA-Biome sequencing to identify novel relationships between the gut and salivary microbiota and the immune system in dysglycemia (those with prediabetes and diabetes). To better understand the complex dynamic between T-helper cell profiles and SlgA in the gut and saliva in the context of diabetes, we used qPCR to epigenetically quantify T-cell ratios to examine associations.
between the Th17:Treg axis and the gut/salivary IgA-Biomes across the glycemic spectrum [40, 58–61]. Each qPCR assay is specific for either demethylated FOXP3 (for Tregs) or demethylated IL17A (for Th17 cells) [40]. This technique provides relative and absolute immune cell
counts applicable to fresh-frozen blood samples. Signals are digital; they indicate either one positive or negative value per cell rather than arbitrarily defined thresholds for “positivity” as in flow cytometric methods limited to liquid blood. These preliminary analyses identified significant associations by taxa and between alpha and beta diversity metrics of the gut and salivary microbiomes with changes in Th17:Treg ratios in the context of both the IgA-Biome and glycemic status.

Materials and methods

Study population and sample collection

The Diabetes Prevention Microbiome Study is an ongoing longitudinal cohort study designed to explore the complex etiologies of type 2 diabetes and relationships with the gut, nasal, and salivary microbiomes in Mexican American adults residing in Starr County, Texas, where obesity and type 2 diabetes prevalence far exceeds U.S. averages [62]. This study was approved by the Institutional Review Board Committee for the Protection of Human Subjects of the University of Texas Health Science Center (HSC-SPH-06-0225), and informed written consent was obtained from each participant. Stool, saliva, and buffy coat samples were collected upon enrollment from an age matched subset of 24 participants, 8 with normal glycemia, 8 with prediabetes, and 8 with diabetes [13]. Characterization of the gut and salivary IgA-Biomes and demographics of the study participants and were previously published by our group [13]. Briefly, 16.67% (4/24) of subjects were male and the mean age of participants was 47.75 years (standard deviation (SD) = 5.96). The body mass index (BMI) varied by diabetes phenotype (ANOVA = 0.05) with mean BMIs of 30.6 kg/m$^2$ (SD = 4.8), 33.0 kg/m$^2$ (SD = 3.0), and 37.7 kg/m$^2$ (SD = 7.6) for those classified as normoglycemic, prediabetic, and diabetic, respectively.

In the present study, the buffy coats were used to define the Th17:Treg ratio (see below) to establish correlations between the IgA-Biome and diabetes profiles.

Diabetes classifications

Participants were defined as having normoglycemia (n = 8), prediabetes (n = 8), or diabetes (n = 8) based on the clinical cut-points for fasting glucose, 2-hour post load glucose levels, or percent glycated hemoglobin (%HbA1c) [13, 63]. Those with a fasting glucose level of 100 mg/dL–125 mg/dL, a glucose tolerance with a 2-hour post glucose load of 140–199 mg/dL, or with %HbA1c 5.7% < HbA1c < 6.4% were classified as having prediabetes. Participants with a fasting glucose level ≥ 126 mg/dL, a 2-hour post load glucose level ≥ 200 mg/dL, or % HbA1c ≥ 6.5% were classified as having diabetes. Participants with blood values sufficient for classification with prediabetes or diabetes were newly diagnosed and treatment naïve to any diabetes-related medications. A definition of normoglycemic required all 3 measures be within normal range, while an abnormal value on any one test was sufficient to classify a subject as prediabetic or diabetic [13].

IgA-Biome analyses

Bacteria from stool and saliva samples were coated with fluorescently labeled antibodies to separate IgA-coated and uncoated organisms as previously described [13]. Sorting was conducted using a BD SORP FACS Aria™ II (Special Order Research Product from Beckton Dickinson, San Jose, CA), equipped with forward scatter photomultiplier tube (FSC-PMT) for improved small particle detection, at the Baylor College of Medicine Cytometry and Cell Sorting Core [13]. Sorted samples were collected into chilled, pre-labeled epi tubes, and stored at -80°C.
until subjected to 16S rRNA gene sequencing. Most stool and saliva IgA-Biome analyses were conducted on half a million sorted bacteria although some sorts contained fewer bacteria [13].

16Sv4 rDNA sequencing
Genomic DNA was extracted from sorted bacterial cells using the MagAttract PowerSoil DNA kit (Qiagen) following methods adapted from the NIH Human Microbiome Project [64]. In addition to sequencing IgA+ and IgA- bacteria from each sample, unsorted (Presort) samples were collected for each sample prior to sorting and sequenced in parallel. The V4 region of the 16S rDNA gene was amplified by PCR using barcoded primers (515F, 806R) and sequenced on the MiSeq platform (Illumina) via the 2x250 bp paired-end protocol, targeting at least 10,000 reads per sample. The IgA-Biome profiles defined for the 24 participants described in the present study were previously published by our group [13].

Demultiplexed read pairs were merged using USEARCH v7.0.1090 [65] with the following parameters: merged length $\geq$252 bp, minimum 50 bp overlap with zero mismatches, and truncation quality >5. Merged reads were further filtered against a maximum expected error rate of 0.05 and PhiX sequences were removed. Reads were clustered into Operational Taxonomic Units (OTUs) at a similarity cutoff value of 97% using UPARSE [66] and underwent chimera removal via USEARCH [65]. OTUs were mapped against an optimized version of SILVA Database v132 [67] containing only sequences from the v4 region of the 16S rRNA gene.

Epigenetic characterization of T-helper cell profiles
Relative counts of CD3 T-cells, Treg, Th17 subpopulations were measured by quantitative epigenetic real-time PCR at the Berlin laboratory of Precision for Medicine [58]. DNA was extracted fromuffy coats at the German Cancer Research Center from frozen pellets of non-intact, nucleated blood cells (EDTA buffy coats). Buffy coats were collected at the same time stool and saliva samples for IgA-Biome analyses were collected. DNA quality was assessed using Quant-iT PicoGreen dsDNA Assay (Life Technologies) and an OD 260/280 ratio between 1.7 and 2.0 was considered acceptable. Precision for Medicine personnel were blinded to the status of the samples received. Genomic DNA was treated with ammonium bisulphite, converting unmethylated cytosine to uracil while leaving methylated cytosine unchanged, and relative quantities of different lymphocytes were determined through methylation-specific qPCR assays for unmethylated CpG sites that were shown to be stably associated with specific immune cell type lineages as described [59–61]. Absence of CpG methylation in those gene loci (amplicon regions) was used for the epigenetic cell counting. These loci were CD3G/CD3D, FOXP3, and IL-17A for quantification of total CD3+ T-cells, regulatory T-cells (Tregs), and Th17 [59–61]. Total cell count was determined by methylation-specific qPCR for the GAPDH gene locus as described in Sehouli et al. [60]. The relative content of CD3 T-cells, Treg, and Th17 cells in the sample was determined by calculating the ratio of the respective three loci and the number of unmethylated GAPDH genes in the sample. In addition, the relative content of Treg and Th17 cells within the overall CD3 T-cell compartment was determined by calculating the ratios of unmethylated copies for FOXP3/CD3 and IL-17A/CD3 [58, 60, 61]. In addition, the relative composition of pro-inflammatory Th17 cells and immune suppressive Treg cells was calculated based on the copy numbers of unmethylated IL-17A/FOXP3 [58, 60, 61]. All measurements were run in duplicate and subjected to rigorous quality controls according to the laboratory’s quality management system that is accredited under ISO 17025. All plate runs conformed to performance limits set for standards, calibrators, and references that monitor standard linearity, bisulfite conversion, and qPCR efficiency. No samples failed
quality control and the buffy coat samples used for the present study fell within established standards set by a healthy control cohort.

**Statistical analysis**

A two tailed t-test and ANOVA were used to assess Th17:Treg ratios by diabetes phenotypes using Stata 16 statistical software (Statacorp, College Station, TX). As described previously [13], the Agile Toolkit for Incisive Microbial Analyses 2 (ATIMA2) was used as an integrated solution for analyzing and visualizing microbiome data (https://atima.research.bcm.edu). Analyses of alpha diversity metrics were performed in ATIMA2 (supplementary figures) and in Stata 16 using ordinary least squares regression adjusted for body mass index and graphed using GraphPad Prism version 8.0 (San Diego, CA). Comparisons of community dispersion were assessed using unweighted UniFrac distance and visualized using ATIMA2 and statistical significance determined via Mann-Whitney U test or PERMANOVA adjusted for body mass index using the adonis and betadisper functions in the R package vegan [68, 69]. Differentially abundant taxa by Th17:Treg ratios were determined via Linear discriminant analysis effect size (LEfSe) [70] using the Galaxy web platform with parameters of alpha of 0.05 and threshold of logarithmic linear discriminative analysis (LDA) score of 2.0 [71]. Analyses using LEfSe were limited to taxa present in at least 10% of samples and visualized using GraphPad Prism version 8.0.

**Results**

**Epigenetic quantification of the Th17:Treg ratio**

Relative Th17 and Treg cell counts were defined for individuals with previously established stool and salivary IgA-Biomes using quantitative epigenetic real-time PCR and the Th17:Treg ratios calculated (Fig 2) [13]. Comparisons of Th17:Treg ratio between individuals with normoglycemia (n = 8), prediabetes (n = 8), or diabetes (n = 8) identified similarly elevated Th17:Treg ratios in dysglycemic individuals, those classified as having prediabetes (mean ± standard deviation (SD): 2.22±0.20; range: 1.514–3.239) and diabetes (mean ± SD: 1.96±0.19; range: 1.428–3.222), compared to individuals with normal blood sugar values (i.e., normoglycemia; mean ± SD: 1.58±0.16; range: 0.8177–2.006). For this reason, those with prediabetes and diabetes were combined into a dysglycemic category for some of the analyses. The Th17:Treg ratios of those with dysglycemia were significantly higher than those without dysglycemia (Fig 2A; p<0.042). Analyses of differences across the three diabetic phenotypes approached the margin of statistical significance (Fig 1B; ANOVA, p<0.068).

Th17:Treg T-cell ratios were normally distributed (Shapiro-Wilk test of normality p-value = 0.08) with a median of 1.79 and mean of 1.90 (SD: 0.57, range: 0.82–3.24). Consequently, and because there is no established definitions for what constitutes high or low Th17:Treg ratios, the 24 participants were dichotomized into 2 categories above and below the median Th17:Treg ratio, indicative of a (pro-inflammatory profile or anti-inflammatory profile, respectively, for analyses requiring categorical characterization (beta diversity, LEfSe) [40, 72].

**Th17:Treg ratios and glycemic status affect alpha and beta diversity**

The impact of Th17:Treg ratios on the microbiota was first assessed independently of the IgA-Biome by analyzing the Presort samples (i.e. stool and saliva samples not subjected to SIgA⁺ or SIgA⁻ sorting) across the diabetes spectrum. Analyses of alpha diversity, an evaluation of within sample diversity, did not identify differences in bacterial evenness (Shannon diversity
index) between those with normoglycemia or dysglycemia for either the stool or salivary microbiomes by T-cell ratio. Bacterial richness (observed OTUs [operational taxonomic units]) of stool, however, significantly increased with increasing Th17:Treg ratios in those with dysglycemia (Fig 3A; p < 0.005). Although not statistically significant, the opposite trend, *i.e.*, decreasing richness with increasing Th17:Treg ratio, was observed in those with normoglycemia (Fig 3A; p < 0.066). When the same analyses were conducted across the three diabetes phenotypes those with prediabetes and diabetes followed a similar trend *i.e.*, increasing OTUs with increasing Th17:Treg ratios (p < 0.063 and p < 0.035, respectively) (Fig 3B). Analyses of salivary samples did not identify statistically significant differences across the glycemic

Fig 2. Th17:Treg ratios by diabetes profile. Box plots depict the median (center line in each box) and box boundaries represent the range. (A) Th17:Treg ratio comparisons between those with normoglycemia and dysglycemia; *p < 0.042 two-tailed t-test. (B) Th17:Treg ratio comparisons between those with normoglycemia, prediabetes, and diabetes; ANOVA p < 0.0685.

https://doi.org/10.1371/journal.pone.0258812.g002
Fig 3. Impact of Th17:Treg ratios on alpha diversity of the stool microbiome by diabetes phenotype. Linear regression of OTU counts from Presort stool samples on Th17:Treg ratios by (A) normoglycemia and dysglycemia profiles, p-value of <0.066.
spectrum; however, a similar trend to that observed with stool samples was present, i.e., directly and inversely proportional relationships between OTU counts and Th17:Treg ratios for those with dysglycemia and normoglycemia, respectively (S1A and S1B Fig).

Comparisons of individuals grouped as having pro-inflammatory or anti-inflammatory profiles based on Th17:Treg ratios were used to investigate beta, or between sample, diversity of stool and salivary Presort samples using unweighted UniFrac distances, a distance metric that incorporates phylogenetic relatedness and multivariate statistical techniques to determine whether microbial communities are significantly different. Principle coordinate analysis of unweighted UniFrac distances identified significant differences in community composition between individuals with different inflammatory phenotypes in both stool and saliva samples of those with dysglycemia (Fig 4B and 4D; p < 0.021 and p < 0.036, respectively). Significant differences in the stool or saliva Presort samples of those with normoglycemia were not observed (Fig 4A and 4C). Analyses by prediabetes and diabetes phenotypes identified significant differences in the stool microbiome of those with prediabetes (S2 Fig; p < 0.03). No significant differences in the salivary microbiome in those with prediabetes or diabetes were observed (S3 Fig).

Fig 4. Principle coordinate analyses of UniFrac distances of stool and saliva Presort samples by Th17:Treg ratios in those with normoglycemia and dysglycemia. Principal coordinate analyses of unweighted UniFrac distances of stool (A, B) and (C, D) saliva Presort samples in those with (A, C) normoglycemia and (B, D) dysglycemia. P-values determined using PERMANOVA and include adjustments for body mass index.

https://doi.org/10.1371/journal.pone.0258812.g004
We used the biomarker discovery tool Linear Discriminant Analysis Effect Size (LEfSe) [73] to identify preferentially abundant genera in the stool and saliva Presort samples of individuals classified as having pro- or anti-inflammatory profiles (Fig 5). Six organisms were found to be differentially abundant of the stool of those with pro-inflammatory Th17:Treg ratios, including members of the genus *Faecalibacterium* (p = 0.008), while only one genus, *Fusicatenbacter* (p = 0.039), was found to be differentially abundant of the stool of those with an anti-inflammatory profile. In saliva, *Granulicatella* (p = 0.031) and members of genera *Sele-nomonas* (p = 0.036) and *Eubacterium* (p = 0.040) were preferentially abundant in the Presort salivary microbiome of those with anti- and pro-inflammatory Th17:Treg profiles, respectively.
Associations between the IgA-Biome, Th17:Treg ratios, and glycemic status

The observation that almost all human SIgA protein sequences show evidence of somatic hypermutation and affinity maturation indicates that T-cell-dependent responses likely play a dominant role in shaping the IgA-Biome. More specifically as it relates to IgA production, B-cells of the mucosal lymphoid tissues are different from B-cells populating non-mucosal lymphoid tissues in that they can undergo class switching from IgM/IgD to IgA without T-cell help; however, like B-cells at all other anatomic sites, mucosal B-cells cannot produce high affinity antibodies, the products of germinal center reactions and somatic hypermutation, without the aid of T-cells [11, 74]. We therefore evaluated the interaction between Th17:Treg ratios and the IgA-Biome in the context of glycemic status. Linear regression of alpha diversity metrics on Th17:Treg ratios by stool IgA-Biome compartments (SIgA+ and SIgA-) identified significant increases in richness (OTU count) with increasing Th17:Treg ratios in those with dysglycemia in both compartments (Fig 6A; p < 0.001). When the analysis of Th17:Treg ratios and the IgA-Biome was conducted across the three diabetes phenotypes similar trends were observed (Fig 6B; p < 0.132 and p < 0.018 in the IgA+ and IgA- compartments, respectively of those with prediabetes and p < 0.012 and p < 0.022 in the IgA+ and IgA- compartments, respectively of those with diabetes). The opposite trend, although not significant, was observed in normoglycemic individuals, whereby richness decreased in both SIgA compartments as the Th17:Treg ratio increased (Fig 6). Analysis of alpha diversity metrics in the salivary IgA-Biome did not identify significant associations (S4A and S4B Fig).

Principle coordinate analyses of unweighted UniFrac distances (Fig 7) identified significant differences in microbial community composition by Th17:Treg ratio-derived inflammatory phenotypes in the SIgA+ stool samples of those with dysglycemia (Fig 7B; p < 0.003). No differences by inflammatory phenotype were observed in those without diabetes in the SIgA- fraction of stool samples (Fig 7A) nor in either SIgA compartment of the salivary microbiome. Within the dysglycemic group, similar analyses comparing inflammatory phenotype of those with prediabetes and diabetes identified significant differences only in the stool SIgA+ and SIgA- compartments of those with prediabetes (S5 Fig). No significant differences in the salivary IgA-Biome by inflammatory phenotype were observed in subjects with prediabetes or diabetes (S6 Fig).

Comparisons across diabetes phenotypes of unweighted UniFrac distances between each subject within an inflammatory profile, however, revealed significant differences in community composition within the SIgA compartments of stool (Fig 8) and saliva (S7 Fig). The gut microbial communities from individuals with a pro-inflammatory phenotype within the SIgA+ fraction of those with normoglycemia (p < 0.0152) and the SIgA+ fraction in those with dysglycemia (Fig 8; p < 0.023) were significantly less diverse than those with a lower inflammatory profile. In saliva, independent of SIgA coating (i.e., Presort sample) the microbial communities of normoglycemic individuals with a pro-inflammatory profile were more diverse than those with an anti-inflammatory profile (S7 Fig).

LEfSe also identified preferentially abundant genera between individuals with Th17:Treg ratios above and below the median value in both the stool and salivary IgA-Biomes (Fig 9). Similar to what was observed for Presort samples, the genus Faecalibacterium had the highest LDA score in subjects with a pro-inflammatory phenotype in the SIgA+ compartment (p = 0.014). The similarity between taxa identified in both the Presort (Fig 5) and SIgA+ fractions (Fig 9), compared to the taxa present in the SIgA+ fraction, suggested SIgA+ taxa drive the significant associations observed in the Presort analyses. Only Allinsonella was present in both the Presort (p = 0.018) and SIgA+ (0.014) fractions and Faecalibacterium was present across all three compartments (Fig 9). Dominant taxa in the salivary IgA-Biome included
Mogibacterium in the SlgA⁺ compartment of those with a pro-inflammatory phenotype. No significant taxa in the SlgA⁻ compartment in those with a pro-inflammatory phenotype were identified. Analysis of individuals classified as having an anti-inflammatory phenotype identified Cardiobacterium (p = 0.032) and Selenomomas (p = 0.041) as preferentially abundant in the SlgA⁺ compartment and Gemella (p = 0.007), Oribacterium (p = 0.034), and Stomatobaculum (p = 0.024) in the SlgA⁻ compartment.

Discussion

The relationship between the gut microbiome and human health has become increasingly evident [2, 11, 25, 37, 75–82]. We now recognize that disturbances of the gut microbiota trigger ripple effects that impact immunoglobulin production, T-helper cell responses, vaccine efficacy, infection [2, 8, 21, 83–88], metabolism [89–91], nutrition [92], and even the composition of microbiota in the lungs and oral mucosa [11, 21, 93–96]. That the gut microbiome can influence inflammation and host metabolism in a manner consistent with what is observed at the onset of type 2 diabetes, intimates a possible causal role of the gut microbiome in type 2 diabetes initiation or progression [97, 98]. Therefore, identifying the microbial constituents that have the host’s immunological attention or, equally important, organisms that should have the host’s attention but for unknown reasons do not, is critical to fully understanding the complex etiology of type 2 diabetes.
In the present study we aimed to identify associations across the Th17:Treg-SIgA axis and glycemic profiles by studying a population whose stool and salivary IgA-Biomes had been previously characterized [13]. Even with the small sample size examined, these preliminary analyses identified significant differences in alpha and beta diversity metrics and taxonomy across T-cell ratios. Differences were most notable in the stool IgA-Biome using both continuously measured and dichotomized Th17:Treg ratios, with categorical classification based on the premise that higher ratios corresponded to higher inflammatory profiles [40, 72].

Analysis of within-subject variation revealed significant increases in bacterial richness (OTU counts) with increasing Th17:Treg ratios in those with dysglycemia (e.g., prediabetes and diabetes phenotypes combined). When the dysglycemic group was separated into those with prediabetes and diabetes, the association between Th17:Treg ratios and OTU counts persisted. These significant effects held across the unsorted Presort sample and both SIgA compartments (SIgA+ and SIgA−) demonstrating that bacterial richness positively correlated with measures of inflammation only in those with abnormal blood sugar values. Although analyses of saliva did not identify significant associations between relative abundance and Th17:Treg ratios, it should be noted that same trend for those with dysglycemia (increasing Th17:Treg ratios correlated with increasing OTUs) and normoglycemia (increasing Th17:Treg ratios...
correlated with decreasing OTUs) was observed. This pattern implicates a roll for Th17 and Treg cells in shaping the microbiota across the MALT.

The premise that increasing diversity is associated with health may therefore need re-evaluation, particularly in the context of the IgA-Biome [99, 100]. That is, increased diversity may not be beneficial, particularly in SIgA+ or SIgA− fractions, if SIgA responses are focused on microbiota critical to gut homeostasis or if the increase in diversity is the result of an outgrowth of pathobionts associated with disease as observed in some irritable bowel disease patients [11]. A recent study that observed healthy ageing and longevity was associated with reduced microbial diversity and loss of specific taxa further disrupts the paradigm that increased diversity is always healthful [101].

We also observed significant differences in community composition (beta diversity) between individuals categorized by their inflammatory profiles in the stool and salivary microbiomes of those with dysglycemia (Fig 4). In stool, these changes were most strongly associated with the SlgA+ compartment (Fig 7) and may implicate SlgA-coated organisms in the pathological processes associated with higher Th17:Treg ratios and inflammation [102]. A similar but not significant trend in the SlgA+ fraction of those with normal blood sugar values may indicate that changes to SlgA-targeted communities is heightened in the context of an inflammatory disease like type 2 diabetes. It is also remarkable that even in this small data set, a general trend was observed, particularly in stool IgA-Biome compartments and the Presort samples towards decreasing community diversity (i.e., lower UniFrac distance) in individuals with a more inflammatory T-cell profile independent of glycemic status (Fig 8). This suggested...
that individuals with a higher inflammatory profile have communities more similar to each other compared to those with a lower inflammatory profile (Fig 8). This general trend was not observed for the salivary IgA-Biome. In fact, the Presort of those with normoglycemia had the opposite association i.e., less diversity between salivary communities of those with reduced inflammatory profiles compared to those with higher inflammatory profiles (S7 Fig).

Preferentially abundant genera across the IgA-Biome in the context of inflammatory phenotypes based Th17:Treg ratios were identified using LEfSe. In the stool Presort samples, genera significantly associated with pro-inflammatory profiles appeared to be driven by SlgA-targeted organisms since many taxa (Collinsella, Lachnospiraceae, Phascolarctobacterium, and Faecalibacterium) were found enriched in both the Presort and SlgA+ fractions. Parabacteroides and Erysipelotrichaceae were unique to the SlgA+ fraction and Allinsonella and Negativibacillus unique to the stool Presort. The only genus present in both SlgA+ and SlgA– compartments was Faecalibacterium, a genus that only contains 22 species, 12 of which inhabit the human gut [103]. Although F. prausnitzii has been associated with chronic inflammation, other Faecalibacterium species are leading candidates for the development of probiotics and biotherapeutics [103, 104]. It is possible that different Faecalibacterium species/strains with varying levels of antigenicity may be responsible for the presence of this species in both the SlgA+ and SlgA– compartments; similar to the two strains of Bacteroides fragilis described by Palm et al., one associated with irritable bowel disease and the other with a healthy gut [102]. Identification of Collinsella was also interesting since increasing relative abundance of this organism has previously been positively correlated to diabetes and negatively correlated to weight loss, suggesting that manipulation/reduction of diabetes-associated taxa such as Collinsella may be an avenue through which to improve glucose homeostasis [105–107].

Although the predominance of our findings involved the gut, developing an understanding of the salivary IgA-Biome in the context of health and disease may be as important since i) the oral mucosa is the first point of contact between SlgA and the microbiota, ii) SlgA responses stimulated at distinct mucosal sites recirculate between compartments thereby affecting each site’s SlgA responses, iii) many SlgA-targeted oral microbiota can be detected in the gut, and iv) oral dysbiosis impacts gut microbiome homeostasis [11, 108]. Although the differences observed in the salivary IgA-Biome in the present analyses were not as striking as those described for the gut IgA-Biome, our small sample size and the fewer number of taxa that colonize the oral mucosa (relative to the number colonizing the gut) may have muted our sensitivity to alterations in salivary microbiota with changing Th17:Treg ratios [108]. Nevertheless, we observed significant changes in salivary IgA-Biome beta diversity between individuals dichotomized by Th17:Treg ratio in those with dysglycemia. This supported the hypothesis that inflammatory changes as a consequence of changing Th17:Treg ratios and disease status have fundamental impacts across mucosal-associated lymphoid tissues and that interventions targeting multiple mucosal sites as a means of re-establishing systemic symbiosis across mucosal compartments may be possible.

The role of the gut microbiota in shaping and maintaining immune health cannot be overstated. Gut microbial communities significantly impact the Th17:Treg balance, an association easily appreciated in germ free mice that present with impaired Treg function [24, 100]. Conversely, in both mice and humans, Treg deficiency resulted in chronic inflammation and the elicitation of autoimmune responses in various organs [100] and specific strains of Bacteroides fragilis and Clostridia species have been observed as key drivers of Treg development and suppressors of Th17 responses [24]. We propose a scenario where host factors (e.g., genetics, SlgA) and the environment (e.g., diet, antibiotics, infections) shape a core microbiota. The microbiota, via interactions with immune components such as innate immune receptors in the gut and dendritic cells (in addition to other antigen presenting cells of the lamina propria), establish a cytokine milieu that shapes the T-helper cell profiles of the mucosa. B-cells
responding to the same microbial stimuli will in turn receive help signals from activated T-cells required for the establishment of diverse and specific SlgA. The cycle is completed when SlgA interacts with and re-shapes the microbiota that originally stimulated its generation [11].

Our preliminary results demonstrated that an association exists between dysglycemic status and epigenetically quantified Th17:Treg ratios across the SlgA Biomes. This pilot project is the first of its kind to associate epigenetically quantified Th17:Treg ratios with both the larger and SlgA-fractionated microbiome, assess these associations in the context of a chronic inflammatory disease with increasing global prevalence and offers a novel frame through which to evaluate mucosal microbiomes in the context of host responses and inflammation. Larger sample sizes and deeper analyses into the specific species/strains associated with these phenotypic changes are needed to more fully illuminate the effects of inflammation on the microbiome and will be crucial to developing interventions designed to alter microbial populations as a means of establishing gut/immune homeostasis that in turn drive systemic health.

Supporting information

S1 Fig. Impact of Th17:Treg ratios on alpha diversity of the salivary microbiome by diabetes phenotype. Linear regression of OTU counts from Presort stool samples on Th17:Treg ratios by (A) normoglycemia and dysglycemia profiles, p-value of <0.066 (normoglycemic) and <0.198 (dysglycemic) or (B) by normoglycemia, prediabetes, and diabetes profiles, p-value of p<0.136 (prediabetes) p-value of p<0.381 (diabetes). P-values obtained using ordinary least squares regression and result from a two-sided hypothesis.

S2 Fig. Principle coordinate analyses of UniFrac distances of stool Presort samples by Th17:Treg ratios in those with normoglycemia, prediabetes, and diabetes. Principal coordinate analyses of unweighted UniFrac distances of the stool microbiomes of those with (A) normoglycemia, (B) prediabetes, or (C) diabetes. P-values determined using PERMANOVA.

S3 Fig. Principle coordinate analyses of UniFrac distances of saliva Presort samples by Th17:Treg ratios in those with normoglycemia, prediabetes, and diabetes. Principal coordinate analyses of unweighted UniFrac distances of the stool microbiomes of those with (A) normoglycemia, (B) prediabetes, or (C) diabetes. P-values determined using PERMANOVA.

S4 Fig. Impact of Th17:Treg ratios on alpha diversity of the saliva IgA-Biome by diabetes phenotype. (A) Linear regression of OTU counts on Th17:Treg ratios in those individuals with normoglycemia and dysglycemia. Normoglycemic p<0.958 and p<0.359 in the IgA+ and IgA- compartments, respectively, and dysglycemic p<0.715 and p<0.533 in the IgA+ and IgA- compartments, respectively. (B) Linear regression of OTU counts on Th17:Treg ratios in those individuals with normoglycemia, prediabetes, and diabetes by SlgA coating. For those individuals with normoglycemia, p<0.958 and p<0.359 in the IgA+ and IgA- compartments, respectively, for those individuals with prediabetes, p<0.819 and p<0.376 in the IgA+ and IgA- compartments, respectively, and in those with diabetes, p<0.097 and p<0.567 in the IgA+ and IgA- compartments, respectively.

S5 Fig. Principal coordinate analyses of UniFrac distances of the stool IgA-Biome by dichotomized Th17:Treg ratios across diabetes phenotype. Principal coordinate analyses of unweighted UniFrac distances of the (A, B, C) SlgA+ and (C, D, E) SlgA- compartments of
individuals dichotomized by their inflammatory profiles. (A, D) Normoglycemic and (B, E) prediabetic, and (C, F) diabetes. Statistical significance was determined using PERMANOVA.

S6 Fig. Principal coordinate analyses of UniFrac distances of the salivary IgA-Biome by dichotomized Th17:Treg ratios across diabetes phenotype. Principal coordinate analyses of unweighted UniFrac distances of the (A, B, C) SlgA⁺ and (C, D, E) SlgA⁻ compartments of individuals dichotomized by their inflammatory profiles. (A, D) Normoglycemic and (B, E) prediabetic, and (C, F) diabetes. Statistical significance was determined using PERMANOVA.

S7 Fig. Comparisons of UniFrac distances between of the salivary IgA-Biome of normal and dysglycemic individuals categorized by Th17:Treg ratio. Box plots compare unweighted UniFrac distances between all individuals within each inflammatory phenotype, respectively, by SlgA compartment and glycemic profile. *p<0.023 determined using the Mann-Whitney U-test.

Acknowledgments

We would like to thank the participants for their willingness to be a part of our study and the amazing, tireless Starr County Health Studies’ staff that are responsible for enrolling, consenting, and collecting the samples that allow us to conduct our various studies.

Author Contributions

Conceptualization: Heather T. Essigmann, Eric L. Brown.
Data curation: Kristi L. Hoffman.
Formal analysis: Heather T. Essigmann, Craig L. Hanis, Eric L. Brown.
Funding acquisition: Craig L. Hanis, Eric L. Brown.
Investigation: Heather T. Essigmann, Goo Jun, David Aguilar, Craig L. Hanis, Herbert L. DuPont, Eric L. Brown.
Methodology: Heather T. Essigmann, Kristi L. Hoffman, Eric L. Brown.
Project administration: Joseph F. Petrosino, Craig L. Hanis, Eric L. Brown.
Resources: Kristi L. Hoffman, Goo Jun, Herbert L. DuPont, Eric L. Brown.
Supervision: Joseph F. Petrosino, Craig L. Hanis, Eric L. Brown.
Validation: Kristi L. Hoffman.
Visualization: Heather T. Essigmann, Joseph F. Petrosino, Craig L. Hanis, Eric L. Brown.
Writing – original draft: Heather T. Essigmann, Eric L. Brown.
Writing – review & editing: Heather T. Essigmann, Kristi L. Hoffman, Joseph F. Petrosino, Goo Jun, David Aguilar, Craig L. Hanis, Herbert L. DuPont, Eric L. Brown.

References

1. Swiatczak B, Cohen IR. Gut feelings of safety: tolerance to the microbiota mediated by innate immune receptors. Microbiol Immunol. 2015; 59(10):573–85. Epub 2015/08/27. https://doi.org/10.1111/1348-0421.12318 PMID: 26306708.
2. Shulzhenko N, Morgun A, Hsiao W, Battle M, Yao M, Gavriloava O, et al. Crosstalk between B lymphocytes, microbiota and the intestinal epithelium governs immunity versus metabolism in the gut. Nat Med. 2011; 17(12):1585–93. Epub 2011/11/22. https://doi.org/10.1038/nm.2505 PMID: 22101768; PubMed Central PMCID: PMC3902046.

3. Vehkala L, Ukkola O, Kesaniemi YA, Kahonen M, Nieminen MS, Salomaa V, et al. Plasma IgA antibody levels to malondialdehyde acetaldehyde-adducts are associated with inflammatory mediators, obesity and type 2 diabetes. Ann Med. 2013; 45(8):501–10. Epub 2013/10/04. https://doi.org/10.116/medicine.an6619 PMID: 28971969; PubMed Central PMCID: PMC5790183.

4. Bunker JJ, Erickson SA, Flynn TM, Henry C, Koval JC, Meisel M, et al. Natural polyreactive IgA antibodies coat the intestinal microbiota. Science. 2017; 358(6361). Epub 2017/10/04. https://doi.org/10.1126/science.aan6619 PMID: 28971969; PubMed Central PMCID: PMC5790183.

5. Pabst O. New concepts in the generation and functions of IgA. Nat Rev Immunol. 2012; 12(12):821–32. Epub 2012/10/30. https://doi.org/10.1038/nri3322 PMID: 23103985.

6. Cullender TC, Chassing B, Janzon A, Kumar K, Muller CE, Werner JJ, et al. Innate and adaptive immunity interact to quench microbiome flagellar motility in the gut. Cell Host Microbe. 2013; 14(5):571–81. Epub 2013/11/19. https://doi.org/10.1016/j.chom.2013.10.009 PMID: 24237702; PubMed Central PMCID: PMC3920589.

7. Fagarasan S, Muramatsu M, Suzuki K, Nagaoka H, Hiai H, Honjo T. Critical roles of activation-induced cytidine deaminase in the homeostasis of gut flora. Science. 2002; 298(5597):1424–7. Epub 2002/11/16. https://doi.org/10.1126/science.1077336 PMID: 12434060.

8. Kawamoto S, Maruya M, Kato LM, Suda W, Atarashi K, Doi Y, et al. Foxp3(+) T cells regulate immunoglobulin A selection and facilitate diversification of bacterial species responsible for immune homeostasis. Immunity. 2014; 41(1):152–65. Epub 2014/07/16. https://doi.org/10.1016/j.immuni.2014.05.016 PMID: 25017466.

9. Kubinska JL, Round JL. Do antibodies select a healthy microbiota? Nat Rev Immunol. 2016; 16(12):767–74. Epub 2016/11/08. https://doi.org/10.1038/nri.2016.114 PMID: 27818504.

10. Chen K, Magri G, Grasset EK, Cerutti A. Rethinking mucosal antibody responses: IgM, IgG and IgD join IgA. Nat Rev Immunol. 2020. Epub 2020/02/06. https://doi.org/10.1038/s41577-020-0261-1 PMID: 32015473.

11. Huus KE, Petersen C, Finlay BB. Diversity and dynamism of IgA-microbiota interactions. Nat Rev Immunol. 2021. Epub 2021/02/12. https://doi.org/10.1038/s41577-020-00506-1 PMID: 33568782.

12. Cesta MF. Normal structure, function, and histology of mucosa-associated lymphoid tissue. Toxicol Pathol. 2006; 34(5):599–608. Epub 2006/10/28. https://doi.org/10.1080/01926230600865531 PMID: 17067945.

13. Brown EL, Essigmann HT, Hoffman KL, Palm NW, Gunter SM, Sederstrom JM, et al. Impact of Diabetes on the Gut and Salivary IgA Microbiomes. Infect Immun. 2020; 88(12). Epub 2020/09/10. https://doi.org/10.1128/IAI.00301-20 PMID: 32900816; PubMed Central PMCID: PMC7671898.

14. Hand TW, Reboldi A. Production and Function of Immunoglobulin A. Annu Rev Immunol. 2021; 39:695–718. Epub 2021/03/02. https://doi.org/10.1146/annurev-immunol-102119-074236 PMID: 33646857.

15. Madhwani T, McBain AJ. The Application of Magnetic Bead Selection to Investigate Interactions between the Oral Microbiota and Salivary Immunoglobulins. PLoS One. 2016; 11(8):e0158288. Epub 2016/08/03. https://doi.org/10.1371/journal.pone.0158288 PMID: 27483159; PubMed Central PMCID: PMC49703730.

16. Fadlallah J, El Kafsi H, Sterlin D, Juste C, Parizot C, Dorgham K, et al. Microbial ecology perturbation in human IgA deficiency. Sci Transl Med. 2018; 10(439). Epub 2018/05/04. https://doi.org/10.1126/scitransmed.aan1217 PMID: 29720448.

17. Brown EL, Essigmann HT, Hoffman KL, Palm NW, Gunter SM, Sederstrom JM, et al. Impact of Diabetes on the Gut and Salivary IgA Microbiomes. Infect Immun. 2020; 88(12). Epub 2020/09/10. https://doi.org/10.1128/IAI.00301-20 PMID: 32900816; PubMed Central PMCID: PMC7671898.

18. Madhwani T, McBain AJ. The Application of Magnetic Bead Selection to Investigate Interactions between the Oral Microbiota and Salivary Immunoglobulins. PLoS One. 2016; 11(8):e0158288. Epub 2016/08/03. https://doi.org/10.1371/journal.pone.0158288 PMID: 27483159; PubMed Central PMCID: PMC49703730.

19. Lycke N, Eriksen L, Holmgren J. Protection against cholera toxin after oral immunization is thymus-dependent and associated with intestinal production of neutralizing IgA antitoxin. Scand J Immunol. 1987; 25(4):413–9. Epub 1987/04/01. https://doi.org/10.1111/j.1365-3083.1987.tb02208.x PMID: 3576135.

20. Harris NL, Spooner JF, Nembrini C, Merky P, Massacand J, et al. Mechanisms of neonatal mucosal antibody protection. J Immunol. 2006; 177(9):6256–62. Epub 2006/10/24. https://doi.org/10.4049/jimmunol.177.9.6256 PMID: 17056555.

21. Peterson DA, Planer JD, Guruge JL, Xue L, Downey-Virgin W, Goodman AL, et al. Characterizing the interactions between a naturally primed immunoglobulin A and its conserved Bacteroides...
thetaiotaomicroin species-specific epitope in gnotobiotic mice. J Biol Chem. 2015; 290(20):12630–49. Epub 2015/03/22. https://doi.org/10.1074/jbc.M114.633800 PMID: 25795776; PubMed Central PMCID: PMC4432283.

21. Macpherson AJ, Yilmaz B, Limentakis JP, Galan-Vonarburg SC. IgA Function in Relation to the Intestinal Microbiota. Annu Rev Immunol. 2018; 36:359–81. Epub 2018/02/06. https://doi.org/10.1146/annurev-immunol-042617-053238 PMID: 29400985.

22. Macpherson AJ, Gatto D, Sainsbury E, Harriman GR, Hengartner H, Zinkernagel RM. A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science. 2000; 288(5474):2222–6. Epub 2000/06/24. https://doi.org/10.1126/science.288.5474.2222 PMID: 10864873.

23. Ip B, Cifone NA, Belkina AC, DeFuria J, Jagannathan-Bogdan M, Zhu M, et al. Th17 cytokines differentiate obesity from obesity-associated type 2 diabetes and promote TNF alpha production. Obesity (Silver Spring). 2016; 24(1):102–12. Epub 2015/11/19. https://doi.org/10.1002/oby.21243 PMID: 26576827; PubMed Central PMCID: PMC4432283.

24. Omenetti S, Pizarro TT. The Treg/Th17 Axis: A Dynamic Balance Regulated by the Gut Microbiome. Front Immunol. 2015; 6:639. Epub 2016/01/07. https://doi.org/10.3389/fimmu.2015.00639 PMID: 26734006; PubMed Central PMCID: PMC4688084.

25. Viladomiu M, Kivolowitz C, Abdulhamid A, Dogan B, Victoriano J, Castellanos JG, et al. IgA-coated E. coli enriched in Crohn’s disease spondyloarthritis promote Th17-dependent inflammation. Sci Transl Med. 2017; 9(376). Epub 2017/02/10. https://doi.org/10.1126/scitranslmed.aaf9655 PMID: 28179509; PubMed Central PMCID: PMC6159892.

26. Wang M, Chen F, Wang J, Zeng Z, Yang Q, Shao S. Th17 and Treg lymphocytes in obesity and Type 2 diabetic patients. Clin Immunol. 2018; 197:77–85. Epub 2018/09/16. https://doi.org/10.1016/j.clim.2018.09.005 PMID: 30218707.

27. Turner JS, Benet ZL, Grigorova IL. Signals 1, 2 and B cell fate or: Where, when and for how long? Immunol Rev. 2020; 296(1):9–23. Epub 2020/05/30. https://doi.org/10.1111/imr.12865 PMID: 32470215.

28. Yoshitomi H, Ueno H. Shared and distinct roles of T peripheral helper and T follicular helper cells in human diseases. Cell Mol Immunol. 2020. Epub 2020/09/02. https://doi.org/10.1038/s41423-020-00529-z PMID: 32869810.

29. Quan CP, Berneman A, Pires R, Avrameas S, Bouvet JP. Natural polyreactive secretory immunoglobulin A autoantibodies as a possible barrier to infection in humans. Infect Immun. 1997; 65(10):3997–4004. Epub 1997/10/08. PubMed Central PMCID: PMC175574. https://doi.org/10.1128/iai.65.10.3997-4004.1997 PMID: 9316998.

30. Shimoda M, Inoue Y, Azuma N, Kanno C. Natural polyreactive immunoglobulin A antibodies produced in mouse Peyer’s patches. Immunology. 1999; 97(1):9–17. Epub 1999/08/14. https://doi.org/10.1046/j.1365-2567.1999.00755.x PMID: 10447709; PubMed Central PMCID: PMC4268812.

31. Bunker JJ, Flynn TM, Koval JC, Shaw DG, Meisel M, McDonald BD, et al. Innate and Adaptive Humoral Responses Coat Distinct Commensal Bacteria with Immunoglobulin A. Immunity. 2015; 43(3):541–53. Epub 2015/09/01. https://doi.org/10.1016/j.immuni.2015.08.007 PMID: 26320660; PubMed Central PMCID: PMC4575282.

32. Okai S, Usui F, Yokota S, Hori IY, Hasegawa M, Nakamura T, et al. High-affinity monoclonal IgA regulates gut microbiota and prevents colitis in mice. Nat Microbiol. 2016; 1(9):16103. Epub 2016/08/27. https://doi.org/10.1038/nmicrobiol.2016.103 PMID: 27562257.

33. Shinkura R, Ito S, Begum NA, Nagaoka H, Muramatsu M, Kinoshita K, et al. Separate domains of AID are required for somatic hypermutation and class-switch recombination. Nat Immunol. 2004; 5(7):707–12. Epub 2004/06/15. https://doi.org/10.1038/ni086 PMID: 15195091.

34. Wei M, Shinkura R, Doi Y, Maruya M, Fagarasan S, Honjo T. Mice carrying a knock-in mutation of Aicda resulting in a defect in somatic hypermutation have impaired gut homeostasis and compromised mucosal defense. Nat Immunol. 2011; 12(3):264–70. Epub 2011/01/25. https://doi.org/10.1038/ni.2128 PMID: 21258321.

35. Kato LM, Kawamoto S, Maruya M, Fagarasan S. The role of the adaptive immune system in regulation of gut microbiota. Immunol Rev. 2014; 260(1):67–75. Epub 2014/06/20. https://doi.org/10.1111/imr.12185 PMID: 24942682.
Glycemic levels alter IgA-Biome and T-cell profiles

37. Zhou T, Hu Z, Yang S, Sun L, Yu Z, Wang G. Role of Adaptive and Innate Immunity in Type 2 Diabetes Mellitus. J Diabetes Res. 2018; 2018:7457269. Epub 2018/12/12. https://doi.org/10.1155/2018/7457269; PubMed Central PMCID: PMC56250017.

38. Ferraro A, Socci C, Stabilini A, Valle A, Monti P, Piemonti L, et al. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes. 2011; 60(11):2903–13. Epub 2011/09/08. https://doi.org/10.2337/db11-0090; PubMed Central PMCID: 21896832.

39. Zhang C, Xiao C, Wang P, Xu W, Zhang A, Li Q, et al. The alteration of Th1/Th2/Th17/Treg paradigm in patients with type 2 diabetes mellitus: Relationship with diabetic nephropathy. Hum Immunol. 2014; 75(4):289–96. Epub 2014/02/18. https://doi.org/10.1016/j.humimm.2014.02.007 PMID: 24530745.

40. Singh A, Yamamoto M, Ruan J, Choi JY, Gauvreau GM, Olek S, et al. Th17/Treg ratio derived using DNA methylation analysis is associated with the late phase asthmatic response. Allergy Asthma Clin Immunol. 2014; 10(1):32. Epub 2014/07/06. https://doi.org/10.1186/1710-1492-10-32 PMID: 24991220; PubMed Central PMCID: PMC4078401.

41. Feng T, Elson CO, Cong Y. Treg cell-IgA axis in maintenance of host immune homeostasis with microbiota. Int Immunopharmacol. 2011; 11(5):589–92. Epub 2010/11/30. https://doi.org/10.1016/j.intimp.2010.11.016 PMID: 21111079; PubMed Central PMCID: PMC3078992.

42. Cheng X, Yu X, Ding YJ, Fu QQ, Xie JJ, Tang TT, et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol. 2008; 127(1):89–97. Epub 2004/02/26. https://doi.org/10.1016/j.clim.2008.01.009 PMID: 18294918.

43. Dalmas E, Venteclaf N, Caer C, Poitou C, Cremer I, Aron-Wisnewsky J, et al. T cell-derived IL-22 amplifies IL-1beta-driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes. Diabetes. 2014; 63(6):1966–77. Epub 2014/02/13. https://doi.org/10.2337/db13-1511 PMID: 24520123.

44. Xiang L, Cella M, McCartney SA, Fuchs A, Abumrad NA, Pietka TA, et al. Association between specific adipose tissue CD4+ T-cell populations and insulin resistance in obese individuals. Gastroenterology. 2013; 145(2):366–74 e1-3. Epub 2013/04/20. http://doi.org/10.1053/j.gastro.2013.04.016 PMID: 23597726; PubMed Central PMCID: PMC3756481.

45. Chen H, Ren X, Liao N, Wen F. Th17 cell frequency and IL-17A concentrations in peripheral blood mononuclear cells and vitreous fluid from patients with diabetic retinopathy. J Int Med Res. 2016; 44(6):1403–13. Epub 2016/11/26. https://doi.org/10.1177/0300060516672369 PMID: 27885039; PubMed Central PMCID: PMC5536736.

46. Jagannathan-Bogdan M, McDonnell ME, Shin H, Rehman Q, Hasturk H, Apovian CM, et al. Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes. J Immunol. 2011; 186(2):1162–72. Epub 2010/12/21. https://doi.org/10.4049/jimmunol.1002615 PMID: 21169542; PubMed Central PMCID: PMC3089774.

47. Yuan N, Zhang HF, Wei Q, Wang P, Guo WY. Expression of CD4+CD25+Foxp3+ Regulatory T Cells, Interleukin 10 and Transforming Growth Factor beta in Newly Diagnosed Type 2 Diabetic Patients. Exp Clin Endocrinol Diabetes. 2018; 126(2):96–101. Epub 2017/09/28. https://doi.org/10.1055/s-0043-113454 PMID: 28954308.

48. Han JM, Patterson SJ, Speck M, Ehres JA, Leving S. Insulin inhibits IL-10-mediated regulatory T cell function: implications for obesity. J Immunol. 2014; 192(2):623–9. Epub 2013/12/11. https://doi.org/10.4049/jimmunol.1302181 PMID: 24323581.

49. Qiao YC, Shen J, He L, Hong XZ, Tian F, Pan YH, et al. Changes of Regulatory T Cells and of Proinflammatory and Immunosuppressive Cytokines in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Diabetes Res. 2016; 2016:3694957. Epub 2016/10/26. https://doi.org/10.1155/2016/3694957 PMID: 27777959; PubMed Central PMCID: PMC5061980.

50. Awartani F. Serum immunoglobulin levels in type 2 diabetes patients with chronic periodontitis. J Contemp Dent Pract. 2010; 11(3):001–8. Epub 2010/05/13. PMID: 20461318.

51. Triolo G, Giardina E, Zarcone MR, Giordano C, Rinaldi A, Bompiani GD. Contribution of secretory IgA, polymeric IgA and IgA/secretory component-containing circulating immune complexes to the serum hyper-IgA in diabetes mellitus. Diabetologia. 1984; 27 Suppl:157–9. Epub 1984/07/01. https://doi.org/10.1007/BF00275677 PMID: 6479489.

52. Gregg EW, Sattar N, Ali MK. The changing face of diabetes complications. Lancet Diabetes Endocrinol. 2016; 4(6):537–47. Epub 2016/05/09. https://doi.org/10.1016/S2213-8587(16)30010-9 PMID: 27156051.

53. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014; 105(2):141–50. Epub 2014/05/07. https://doi.org/10.1016/j.diabres.2014.04.006 PMID: 24798950.
54. Zhou W, Sailani MR, Contrepois K, Zhou Y, Ahadi S, Leopold SR, et al. Longitudinal multi-omics of host-microbe dynamics in prediabetes. Nature. 2019; 569(7758):663–71. Epub 2019/05/31. https://doi.org/10.1038/s41586-019-1236-x PMID: 31142858; PubMed Central PMCID: PMC6666404.

55. Kumar Nathella P, Babu S. Influence of diabetes mellitus on immunity to human tuberculosis. Immunology. 2017; 152(1):13–24. Epub 2017/05/26. https://doi.org/10.1111/imm.12762 PMID: 28543817; PubMed Central PMCID: PMC5543489.

56. Agashe S, Petak S. Cardiac Autonomic Neuropathy in Diabetes Mellitus. Methodist Debakey Cardiovasc J. 2018; 14(4):251–6. Epub 2019/02/23. https://doi.org/10.14797/mdcj-14-4-251 PMID: 30788010; PubMed Central PMCID: PMC6369622.

57. Guo M, Ding J, Li J, Wang J, Zhang T, Liu C, et al. SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab. 2018; 20(8):1977–82. Epub 2018/03/25. https://doi.org/10.1111/dom.13295 PMID: 30788010; PubMed Central PMCID: PMC6369622.

58. Barou J, Werner J, Schildknecht K, Schulze JJ, Mulu A, Liebert UG, et al. Epigenetic immune cell counting in human blood samples for immunodiagnostics. Sci Transl Med. 2018; 10(452). Epub 2018/08/03. https://doi.org/10.1126/scitranslmed.aan3508 PMID: 30068569.

59. Burska AN, Thu A, Parmar R, Bzoma I, Samans B, Raschke E, et al. Quantifying circulating Th17 cells by qPCR: potential as diagnostic biomarker for rheumatoid arthritis. Rheumatology (Oxford). 2019; 58 (11):2015–24. Epub 2019/05/14. https://doi.org/10.1093/rheumatology/kez162 PMID: 31081041.

60. Sehouli J, Loddenkemper C, Comu T, Schwachula T, Hoffmuller U, Grutzkau A, et al. Epigenetic quantification of tumor-infiltrating T-lymphocytes. Epigenetics. 2011; 6(2):236–46. Epub 2010/10/22. https://doi.org/10.4161/epi.6.2.13755 PMID: 20962591; PubMed Central PMCID: PMC3278789.

61. Wieczorek G, Asemissen A, Model F, Turbachova I, Floess S, Liebenberg V, et al. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res. 2009; 69(2):599–608. Epub 2009/01/17. https://doi.org/10.1158/0008-5472.CAN-08-2361 PMID: 19147574.

62. Hanis CL, Redline S, Cade BE, Bell GI, Cox NJ, Below JE, et al. Beyond type 2 diabetes, obesity and hypertension: an axis including sleep apnea, left ventricular hypertrophy, endothelial dysfunction, and aortic stiffness among Mexican Americans in Starr County, Texas. Cardiovasc Diabetol. 2016; 15:86. https://doi.org/10.1186/s12933-016-0405-6 PMID: 27266869; PubMed Central PMCID: PMC4897940.

63. Standards of medical care in diabetes—2015: summary of revisions. Diabetes Care. 2015; 38 Suppl: S4. Epub 2014/12/30. https://doi.org/10.2337/dc15-S003 PMID: 25537706.

64. Human Microbiome Project C. Structure, function and diversity of the healthy human microbiome. Nature. 2012; 486(7402):207–14. https://doi.org/10.1038/nature11234 PMID: 22699609; PubMed Central PMCID: PMC3564958.

65. Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 2010; 26 (19):2460–1. https://doi.org/10.1093/bioinformatics/btq461 PMID: 20796981.

66. Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat Methods. 2013; 10(9):996–8. Epub 2013/08/21. https://doi.org/10.1038/nmeth.2604 PMID: 23955772.

67. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, et al. Metagenomic biomarker discovery and explanation. Genome Biol. 2011; 12(6):R60. Epub 2011/06/28. https://doi.org/10.1186/gb-2011-12-6-60 PMID: 21702898; PubMed Central PMCID: PMC3218848.

68. Jari Oksanen FGB, Michael Friendly, Roeland Kindt, Pierre Legendre, Dan McGlinn, Peter R. Minchin, et al. Vegan: Community Ecology Package. R package version 2.5–7. 2020.

69. Team R. RStudio: Integrated development for R. Boston, MA: RStudio, PBC; 2020.

70. Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X, et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009;60(5):1472–83. Epub 2009/05/01. https://doi.org/10.1002/art.24499 PMID: 19404966.

71. Madan A, Thompson D, Fowler JC, Ajami NJ, Salas R, Frueh BC, et al. The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental
illness. J Affect Disord. 2020; 264:98–106. Epub 2020/02/15. https://doi.org/10.1016/j.jad.2019.12.020 PMID: 32056780.

74. Brown EL, Essigmann HT. Original Antigenic Sin: the Downside of Immunological Memory and Implications for COVID-19. mSphere. 2021; 6(2). Epub 2021/03/12. https://doi.org/10.1128/mSphere.00056-21 PMID: 33692194.

75. Vuong HE, Hsiao EY. Emerging Roles for the Gut Microbiome in Autism Spectrum Disorder. Biol Psychiatry. 2017; 81(5):411–23. Epub 2016/10/25. https://doi.org/10.1016/j.biopsych.2016.08.024 PMID: 27773355; PubMed Central PMCID: PMC5285286.

76. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet. 2012; 13(4):260–70. Epub 2012/03/14. https://doi.org/10.1038/nrg3182 PMID: 22411464; PubMed Central PMCID: PMC3418802.

77. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol. 2009; 6(5):306–14. Epub 2009/05/01. https://doi.org/10.1038/nrgastro.2009.35 PMID: 19404271; PubMed Central PMCID: PMC3817714.

78. Shreiner AB, Kao JY, Young VB. The gut microbiome in health and in disease. Curr Opin Gastroenterol. 2015; 31(6):411–23. Epub 2016/10/25. https://doi.org/10.1097/MOG.000000000000139 PMID: 27773355; PubMed Central PMCID: PMC5285286.

79. Tang WH, Kitai T, Hazen SL. Gut Microbiota in Cardiovascular Health and Disease. Circ Res. 2017; 120(7):1183–96. Epub 2017/04/01. https://doi.org/10.1161/CIRCRESAHA.117.309715 PMID: 28360349; PubMed Central PMCID: PMC5930330.

80. Tilg H, Moschen AR. Microbiota and diabetes: an evolving relationship. Gut. 2014; 63(9):1513–21. Epub 2014/05/17. https://doi.org/10.1136/gutjnls-2014-306928 PMID: 24836364.

81. van Olden C, Groen AK, Nieuwdorp M. Role of Intestinal Microbiome in Lipid and Glucose Metabolism in Diabetes Mellitus. Clin Ther. 2015; 37(6):1172–7. Epub 2015/04/30. https://doi.org/10.1016/j.clinthera.2015.03.008 PMID: 25922340.

82. Webb DR, Khunti K, Silverman R, Gray LJ, Srinavan B, Lacy PS, et al. Impact of metabolic indices on central artery stiffness: independent association of insulin resistance and glucose with aortic pulse wave velocity. Diabetologia. 2010; 53(6):1190–8. Epub 2010/03/10. https://doi.org/10.1007/s00125-010-1689-9 PMID: 20213236.

83. Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A. 2009; 106(10):3698–703. Epub 2009/02/24. https://doi.org/10.1073/pnas.0812874106 PMID: 19234110; PubMed Central PMCID: PMC2656143.

84. De Angelis M, Montemurro E, Piccolo M, Vannini L, Lauriero G, Maranzano V, et al. Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN). PLoS One. 2014; 9(6):e99006. Epub 2014/06/13. https://doi.org/10.1371/journal.pone.0099006 PMID: 24922509; PubMed Central PMCID: PMC4055632.

85. Kayama H, Okumura R, Takeda K. Interaction Between the Microbiota, Epithelia, and Immune Cells in the Intestine. Annu Rev Immunol. 2020; 38:33–48. Epub 2020/04/29. https://doi.org/10.1146/annurev-immunol-070119-115104 PMID: 32340570.

86. McCarville JL, Chen GY, Cuevas VD, Troha K, Ayres JS. Microbiota Metabolites in Health and Disease. Annu Rev Immunol. 2020; 38:147–70. Epub 2020/04/29. https://doi.org/10.1146/annurev-immunol-071219-125715 PMID: 32340573.

87. Hagan T, Cortese M, Rouphael N, Boudreau C, Linde C, Maddur MS, et al. Antibiotics-Driven Gut Microbiome Perturbation Alters Immunity to Vaccines in Humans. Cell. 2019; 178(6):1313–28 e13. Epub 2019/09/07. https://doi.org/10.1016/j.cell.2019.08.010 PMID: 31491384; PubMed Central PMCID: PMC6750738.

88. Pamer EG. Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science. 2016; 352(6285):535–8. Epub 2016/04/30. https://doi.org/10.1126/science.aad9382 PMID: 27126035; PubMed Central PMCID: PMC4984266.

89. Cresci GAM. Metabolome of the Microbiome: A Foundation for Better Health? Altern Ther Health Med. 2018; 24(S1):61–5. Epub 2019/04/15. PMID: 30982013.

90. Yang Y, Misra BB, Liang L, Bi D, Weng W, Wu W, et al. Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancer. Theranostics. 2019; 9(14):4101–14. Epub 2019/07/10. https://doi.org/10.7150/thno.35186 PMID: 31261534; PubMed Central PMCID: PMC6592169.

91. Tang ZZ, Chen G, Hong Q, Huang S, Smith HM, Shah RD, et al. Multi-Omic Analysis of the Microbiome and Metabolome in Healthy Subjects Reveals Microbiome-Dependent Relationships Between Diet and Metabolites. Front Genet. 2019; 10:454. Epub 2019/06/06. https://doi.org/10.3389/fgene.2019.00454 PMID: 31164901; PubMed Central PMCID: PMC6534069.
92. Kolodziejczyk AA, Zheng D, Elinav E. Diet-microbiota interactions and personalized nutrition. Nat Rev Microbiol. 2019; 17(12):742–53. Epub 2019/09/22. https://doi.org/10.1038/s41579-019-0256-8 PMID: 31541197.

93. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012; 336(6086):1268–73. Epub 2012/06/08. https://doi.org/10.1126/science.1223490 PMID: 2264334; PubMed Central PMCID: PMC4420145.

94. Barko PC, McMichael MA, Swanson KS, Williams DA. The Gastrointestinal Microbiome: A Review. J Vet Intern Med. 2018; 32(1):9–25. Epub 2017/11/25. https://doi.org/10.1111/jvim.14875 PMID: 29171095; PubMed Central PMCID: PMC5787212.

95. Noverr MC, Huffnagle GB. Does the microbiota regulate immune responses outside the gut? Trends Microbiol. 2004; 12(12):562–8. Epub 2004/11/13. https://doi.org/10.1016/j.tim.2004.10.008 PMID: 15539116.

96. Brandtzaeg P. Do salivary antibodies reliably reflect both mucosal and systemic immunity? Ann N Y Acad Sci. 2007; 1098:288–311. Epub 2007/04/17. https://doi.org/10.1196/annals.1384.012 PMID: 17435136.

97. Bleau C, Karolis AD, St-Pierre DH, Lamontagne L. Crosstalk between intestinal microbiota, adipose tissue and skeletal muscle as an early event in systemic low-grade inflammation and the development of obesity and diabetes. Diabetes Metab Res Rev. 2015; 31(6):545–61. https://doi.org/10.1111/dmrr.2017 PMID: 25352002.

98. Moreno-Indias I, Cardona F, Tinahones FJ, Queipo-Ortuno MI. Impact of the gut microbiota on the development of obesity and type 2 diabetes mellitus. Front Microbiol. 2014; 5:190. https://doi.org/10.3389/fmicb.2014.00190 PMID: 26171753; PubMed Central PMCID: PMC5787212.

99. Petersen C, Round JL. Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol. 2014; 16(10):1202–33. Epub 2014/05/07. https://doi.org/10.1111/cmi.2013.16.10.02 PMID: 24798552; PubMed Central PMCID: PMC4143175.

100. Wilmanski T, Diener C, Rappaport N, Patwardhan S, Wiedrick J, Lapidus J, et al. Gut microbiome pattern reflects healthy ageing and predicts survival in humans. Nat Metab. 2021; 3(2):274–86. Epub 2021/02/24. https://doi.org/10.1038/s42255-021-00336-y PMID: 33619379.

101. De Filippis F, Pasolli E, Ercolini D. Newly Explored Faecalibacterium Diversity Is Connected to Age, Lifestyle, Geography, and Disease. Curr Biol. 2020; 30(24):4932–43 e4. Epub 2020/10/17. https://doi.org/10.1016/j.cub.2020.09.063 PMID: 33065106.

102. Laursen MF, Laursen RP, Larnkjær A, Molgaard KF, Frokiaer H, et al. Faecalibacterium Gut Colonization Is Accelerated by Presence of Older Siblings. mSphere. 2017; 2(6). Epub 2017/05/12. https://doi.org/10.1093/mSphere.00448-17 PMID: 2902044; PubMed Central PMCID: PMC5705805.

103. Lambeth SM, Carson T, Lowe J, Marraja T, Leff JW, Luo L, et al. Composition, Diversity and Abundance of Gut Microbiome in Prediabetes and Type 2 Diabetes. J Diabetes Obes. 2015; 2(3):1–7. Epub 2016/01/13. https://doi.org/10.15436/2376-0949.15.031 PMID: 26756039; PubMed Central PMCID: PMC4705851.

104. Zhang X, Shen D, Fang Z, Jie Z, Qiu X, Zhang C, et al. Human gut microbiota changes reveal the progression of glucose intolerance. PLoS One. 2013; 8(8):e71108. Epub 2013/09/10. https://doi.org/10.1371/journal.pone.0071108 PMID: 24013136; PubMed Central PMCID: PMC3754989.

105. Walker AW, Ince J, Duncan SH, Webster LM, Holtrop G, Ze X, et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J. 2011; 5(2):220–30. Epub 2010/08/06. https://doi.org/10.1038/ismej.2010.118 PMID: 20686513; PubMed Central PMCID: PMC3105703.

106. Silva-Boghossian CM, Cesario PC, Leao ATT, Colombo APV. Subgingival microbial profile of obese women with periodontal disease. J Periodontol. 2018; 89(2):186–94. Epub 2018/03/10. https://doi.org/10.1002/JPER.17-0236 PMID: 29520825.